The prevalence of the BC types varies between the studies and was reported between 31–86% for luminal A type, 6–16% luminal B, 2–16% HER2-enriched and 4–26% for triple-negative (TNBC or basal-like) tumors [8]. Here, ERBB2 is linked to breast cancer.